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Summary Eighty-five breast carcinomas from the same number of patients have been assessed immunohisto-
chemically using the antiserum 21N for the presence of the c-erbB-2 protein. Twenty-two of the patients had
evidence of advanced disease (tumour fixation or distant metastases) at presentation. Follow-up was for a
median of 24 months. c-erbB-2 protein was detected in the majority of cells in 14 (16.5%) carcinomas, and to
a lesser extent in a further six (7%) tumours. There was no relationship between staining and stage, node
status or size but more poorly differentiated carcinomas had evidence of staining (36%) than well (17%) or
moderately (14%) differentiated carcinomas (P=0.02). There was a significant association between staining
and mortality (P=0.009) and recurrence (P=0.0002). The relative risk of death for staining compared to no
staining (after adjusting for node status, stage and grade) was 2.97 (95% confidence interval 1.29, 6.84) and
the relative risk of recurrence for staining compared to no staining after similar adjustment was 3.85 (95%
confidence interval 1.86-7.97). In this particular group of patients immunoreactivity for c-erbB-2 protein is an
independent indicator of poor short-term prognosis.
Breast carcinoma is the commonest type-of cancer occurring
in women and is the main cause of death from cancer.
Despite changes in the management of the disease, survival
figures have not significantly altered over the years. There is
a need to identify those patients who, even though at an
early stage of the disease at presentation, do badly, and who
would benefit from additional therapy. The standard
methods for predicting tumour behaviour have been node
status, stage and tumour differentiation (Haybittle et al.,
1982). Problems arise due to decreasing frequency of axillary
lymph node sampling, and difficulties in the widespread
application of tumour grading.
Several different aspects of breast cancer phenotype have
been assessed for their effect on prognosis. Recent studies,
though, have been concerned with genotype and in
particular the organisation of various proto-oncogenes in
breast carcinomas and their relationship to prognosis.
Several groups have reported that amplification of the c-
erbB-2 (neu) oncogene occurs in breast cancers (King et al.,
1985; Slamon et al., 1987; van de Vijver et al., 1987; Varley
et al., 1987; Zhou et al., 1987) and that this correlates with
poor short-term prognosis (Slamon et al., 1987; Varley et al.,
1987; Zhou et al., 1987).
Analysis of gene organisation relies on the extraction of
DNA from tissues and is not generally applicable. Several
studies have shown that detection of the c-erbB-2 protein,
using immunohistochemistry applied to routinely fixed,
paraffin embedded tissue, relates to amplification of the c-
erbB-2 gene (Venter et al., 1987; van de Vijver et al., 1988a;
Berger et al., 1988; Walker et al., 1989). Since detection of
c-erbB-2 protein was shown to relate to tumour variables
having prognostic significance, some (Venter et al., 1987;
Berger et al., 1988) considered that immunostaining for c-
erbB-2 protein could act as a prognostic marker. However
three studies to date (van de Vijver et al., 1988b; Barnes et
al., 1988; Gusterson et al., 1988) have not found a significant
correlation with clinical outcome, while one other (Wright et
al., 1989) has. The period of follow-up has varied between
the different groups.
In this study expression of c-erbB-2 protein has been
assessed immunohistochemically in carcinomas from patients
presenting at different stages of the disease, with emphasis
on its value in predicting short-term prognosis.
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Materials and methods
Patients
Eighty-five carcinomas from the same number of patients
were studied. All had been excised at Leicester Royal
Infirmary between May 1981 and May 1985. Twenty-two
patients had evidence of an advanced stage, with either
tumour fixation or distant metastasis at presentation.
Follow-up ranged from 3 to 76 months with a median of 24
months. Thirty-one patients had died, 10 of these being
those with advanced disease. A further seven patients had
developed metastatic disease, these all being early stage at
presentation.
Immunohistochemistry
Samples from all carcinomas were fixed in 4% formaldehyde
in saline for 24 hours as block-sized pieces, then routinely
processed through to paraffin wax.
The polyclonal antiserum 21N, which was raised in rabbit
against a synthetic C-terminal peptide of the c-erbB-2
protein, was used throughout (Gullick et al., 1987). The
optimum concentration for use was determined using a
breast carcinoma with a known gene amplification of 10-
fold. Four micrometre sections were dewaxed and
rehydrated. Endogenous peroxidase was blocked by
incubation for 30min in 3% H202 in methanol. Non-specific
binding was inhibited by incubation with normal swine
serum diluted 1:5 for 10min. The sections were then
incubated with 21N diluted in Tris-buffered saline to
3 gml-1 for 90min at room temperature. After washing in
Tris-buffered saline, biotinylated anti-rabbit immunoglobulin
antiserum was applied, followed by pre-formed avidin-
biotinylated peroxidase complex (ABC) (Hsu & Raine,
1981). All secondary reagents were obtained from Dako Ltd.
Peroxidase was detected by the diaminobenzidine-hydrogen
peroxide reaction. Controls were the use of antiserum
absorbed with the peptide (1 mgml1).
Histology
Haematoxylin and Eosin stained sections of all cases were
assessed for type using WHO criteria, and for histological
differentiation using a modification of the Bloom and
Richardson criteria (Elston et al., 1982).
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Statistics
The x2 test was used to evaluate the statistical significance of
the relationship between staining and other established prog-
nostic variables. Cox regression analysis was used to test
associations between staining and morbidity and mortality,
after adjustment for other prognostic variables.
Results
There were 20 (23.5%) carcinomas with evidence of c-erbB-2
protein expression in which the reaction was localised to cell
membranes (Figure 1). For 14 (16.5%) of these, staining of
tumour cells was throughout most of the section, although
small groups of cells were negative, but six carcinomas had
only small areas of the tumour reacting. Weak cytoplasmic
staining was seen in several of the carcinomas with obvious
membrane staining, but was also present in eight carcinomas
with no membrane reactivity. Since previous studies have
shown that it is membrane staining which correlates with
gene amplification (Gusterson et al., 1987; Venter et al.,
1987) these were not included in the positive group.
Seventy-one carcinomas were of the infiltrating ductal
type, eight were infiltrating lobular carcinomas, two were
mucinous carcinomas and there were one each of medullary
and papillary tumours. All carcinomas which expressed
c-erbB-2 protein were infiltrating ductal in type. One
infiltrating lobular carcinoma had weak cytoplasmic staining.
None of the other specialised types of tumour showed any
reactivity.
There was no significant association between staining and
whether the disease was at an early or advanced stage
(X2 =0.5; n.s.) and between staining and node status
(X2=0.54; n.s.) (Table I). It was not possible to assess
reactivity in relation to the number of nodes containing
metastatic tumour. More poorly differentiated tumours had
evidence of staining (36%) than well differentiated (17%) or
moderately differentiated (14%) (X2 =5.4, P-=0.02). The
relationship between staining and tumour size was examined
for those early stage carcinomas which were node positive or
2cm or greater but was not significant (X2=0.54; n.s.).
Of the 20 patients whose carcinomas had evidence of
c-erbB-2 immunoreactivity, 13 (65%) had died, four had
developed recurrent disease and only three were free from
disease. This contrasted with the outcome of the 65 patients
whose tumours were negative, of whom 18 (27.7%) had died,
with a further three developing recurrent disease. Overall
disease free and survival curves are shown in Figure 2.
Cox's proportional hazards regression model was fitted to
the data. Grade, stage and node status were automatically
entered into the model and the association of staining and
mortality was then tested. Staining had a significant
association with mortality (X2 =6.84 on 1 df, P=0.009). The
relative risk of death if staining had occurred as compared to
no staining (having adjusted for the other variables) was 2.97
with 95% confidence interval (1.29, 6.84). There was no
significant differences in the effect of staining on mortality
for the different grades, stages or node status.
The same method was used to consider the relationship
with recurrence. There was a significant association between
staining and recurrence (X2 = 13.75, 1 df, P=0.0002) when all
other variables had been entered into the model. The relative
risk of recurrence for staining compared to no staining,
when adjusted for all the other variables, was 3.85 (95%
confidence interval 1.86-7.97). Again there was no significant
difference in the effect of staining on recurrence for the
different grades, stages or node status.
Discussion
Several studies have shown that the membrane staining of
breast carcinoma cells obtained by immunohistochemistry
Figure 1 Infiltrating duct carcinoma showing homogenous
membrane staining for c-erbB-2 protein. Magnification x 250.
Table I Correlation between c-erbB-2 staining and stage, node
status and grade
Membrane staining
n Absent Present
Stage
Early 63 48 15 n.s.
Advanced 22 17 5
Node status
Free from metastasis 27 22 5 n.s.
Metastasis 58 43 15
Grade
I 6 5 1 P=0.02
II 43 37 6
III 36 23 13
using the antiserum 21N (Venter et al., 1987; Gusterson et
al., 1987; Walker et al., 1989) and other antibodies to c-
erbB-2 protein (Van de Vijver, 1988a,b) is a reliable marker
of c-erbB-2 gene amplification. Immunohistochemical
evaluation of formalin-fixed, paraffin-embedded tissue is
simpler and has a greater potential for widespread
application than the DNA analysis by Southern blotting
required to detect amplification.
There appears to be conflicting findings about the
significance of c-erbB-2, both from gene amplification and
protein expression studies. The frequency of c-erbB-2
amplification as assessed by DNA analysis has ranged from
10% (Ali et al., 1988), 17% (Varley et al., 1987) to 30%
(Slamon et al., 1987). Immunohistochemical studies have
likewise varied. Barnes et al. (1988) found strong staining
indicative of gene amplification in only 9%, but detected
weaker staining in a further 21% of tumours. Gusterson et
al. (1988) described significant staining in 14% of
carcinomas, as did van de Vijver et al. (1988b). In the
present study 16.5% of carcinomas had striking staining for
c-erbB-2, while a further 7% showed a lesser degree of
membrane reactivity. The carcinomas with lesser degrees of
staining showed correlations similar to those with greater
reactivity, a finding similar to that of Barnes et al. (1988),
leading to the conclusion that any degree of membrane428 R.A. WALKER et al.
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Figure 2 Actuarial curves for: (a) overall survival in patients
with (x) and without (0) c-erbB-2 protein expression
(P<0.009); (b) disease-free interval in patients with (x) and
without (0) c-erbB-2 protein expression (P<0.0002).
staining is of significance. Cytoplasmic staining has been
reported by others who have used the antiserum 21N, and its
relevance remains uncertain. Gusterson et al. (1988) have
reported that the weak cytoplasmic staining seen in some
cases without membrane reactivity can be seen in many
tissues when the concentration of antibody is increased and
can also be seen in MCF7 cells which do not show
expression of c-erbB-2 mRNA.
A correlation between c-erbB-2 amplification and lymph
node status has been suggested by some (Slamon et al., 1987;
Zhou et al., 1987) but not by others (Varley et al., 1987; Ali
et al., 1988). Other immunohistochemical studies have also
failed to find a correlation between staining and lymph node
status (Barnes et al., 1988; Gusterson et al., 1988; van de
Vijver et al., 1988b). We were unable to sub-divide the node
positive groups in relation to the number of nodes involved.
There was no association between overexpression and
tumour size, which differs from the findings of van de Vijver
et al. (1988b). The frequency of staining was greater in the
poorly differentiated tumours. This has also been reported
by Barnes et al. (1988) and Berger et al. (1988) but no such
association was found by van de Vijver et al. (1987) or Zhou
et al. (1987).
Several studies concerned with c-erbB-2 gene amplification
have concluded that it is a marker of poor prognosis
(Slamon et al., 1987; Varley et al., 1987; Zhou et al., 1987)
although others have not (Ali et al., 1988). Barnes et al.
(1988) examined, using the same antisera, 195 carcinomas
with a 10-year follow-up period and found no significant
association between staining and clinical outcome although
there was a tendency for patients with stained tumours to
have a worse prognosis. Gusterson et al. (1988) found that c-
erbB-2 protein expression was not of prognostic significance.
Van de Vijver et al. (1988b) considered only stage II
carcinomas; overall survival was reduced significantly in
those patients whose tumours showed c-erbB-2 protein over-
expression but this did not remain significant after
adjustment for tumour size. The present study included both
early and advanced stages but even after adjustment for
node status, stage and grade there was a significant
correlation between staining for c-erbB-2 protein and
development of recurrence and mortality. The median
follow-up of the patients was 24 months and was therefore
shorter than other studies. It is appreciated that the overall
numbers within the study are small, with wide confidence
intervals, but for both recurrence and overall survival the
relative hazards for the staining group compared to the non-
staining group remain significant at both extremes of the
95% confidence intervals. The reasons for the differences
between the different studies may be due to the numbers,
assessed, the selection of patients, unequal follow-up and the
effect of differing therapeutic regimes. However, the findings
from this immunohistochemical study and those of Wright et
al. (1989) indicate that c-erbB-2 protein expression could be
a significant independent indicator of prognosis.
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